Neurological Research Update: Brain Lesions, Dementia Biomarkers, and Multiple Sclerosis Findings

Neurological Research Update: Brain Lesions, Dementia Biomarkers, and Multiple Sclerosis Findings

A recent case report published in Emerging Infectious Diseases documented brain lesions in a 60-year-old Spanish patient that initially appeared similar to metastatic cancer but were later identified as neurocysticercosis. The misdiagnosis highlights the importance of considering infectious causes when evaluating atypical brain lesions.

Cross-sectional analysis revealed that an Alzheimer’s disease blood biomarker test failed to detect over half of amyloid PET-positive cases among veterans with traumatic brain injury history who were either cognitively normal or experiencing mild cognitive impairment, according to findings in JAMA Neurology.

Research published in Alzheimer’s & Dementia demonstrated a correlation between disrupted sleep patterns and accumulation of amyloid beta proteins in brain tissue analyses.

Investigators analyzing six cohort studies found that elevated plasma growth differentiation factor 15 (GDF15) levels in midlife were associated with a 15-25 year increased risk of developing dementia, as reported in Science Advances.

A meta-analysis indicated that individuals carrying two copies of the APOE4 allele (homozygotes) in the Japanese population showed lower Alzheimer’s disease risk compared to previous estimates when measured against APOE3 homozygotes, per findings in Molecular Neurodegeneration.

Spanish retrospective data showed that ovarian reserve markers did not predict disease progression in women with multiple sclerosis, according to research published in Journal of Neurology, Neurosurgery & Psychiatry.

Researchers identified two distinct autism subtypes based on language abilities, intellectual functioning, and adaptive skills in late childhood and adulthood, as detailed in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.

The FDA announced it will convene an advisory committee meeting on July 29 to evaluate deramiocel, an investigational cell therapy for Duchenne muscular dystrophy developed by Capricor Therapeutics. The therapy had previously been rejected by the FDA in 2025, which requested additional data before approval.

Former NFL running back Chris Johnson, who played for the Tennessee Titans, announced at age 39 that he had been diagnosed with amyotrophic lateral sclerosis (ALS), according to Associated Press.

The Guardian covered a case of a man who lived eight years believing he had Parkinson’s disease before discovering his actual diagnosis was different.

Source link